Correction to: Nrf2 is required to maintain the self-renewal of glioma stem cells (BMC Cancer, (2013), 13, 1, (380), 10.1186/1471-2407-13-380);Nrf2 is required to maintain the self-renewal of glioma stem cells

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Zhu, Jianhong ^a   Wang, Handong ^b   Sun, Qing ^a   Ji, Xiangjun ^a   Zhu, Lin ^b   Cong, Zixiang ^a   Zhou, Yuan ^b   Liu, Huandong ^c   Zhou, Mengliang ^b  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b JINLING HOSPITAL   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BMI1 PROTEIN; CYCLIN E; LENTIVIRUS VECTOR; NESTIN; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR NRF2; TRANSCRIPTION FACTOR SOX2; NFE2L2 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER STEM CELL; CARCINOGENESIS; CELL CYCLE G2 PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL RENEWAL; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; GENE SILENCING; GENETIC TRANSFECTION; GLIOMA CELL; GLIOMA STEM CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; FLOW CYTOMETRY; GLIOMA; METABOLISM; NUDE MOUSE; PATHOLOGY; PLURIPOTENT STEM CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; FLOW CYTOMETRY; GENE KNOCKDOWN TECHNIQUES; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; NEOPLASTIC STEM CELLS; NF-E2-RELATED FACTOR 2; PLURIPOTENT STEM CELLS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 84881121768     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-021-08338-x     Document Type: Erratum

References (48)

1. Bartek JJ, Ng K, Bartek J, Fischer W, Carter B, Chen CC. Key concepts in glioblastoma therapy. J Neurol Neurosurg Psychiatr 2012, 83(7):753-760. 10.1136/jnnp-2011-300709, 22396442.
2. Johannessen TC, Bjerkvig R, Tysnes BB. DNA repair and cancer stem-like cells-potential partners in glioma drug resistance. Canc Treat Rev 2008, 34(6):558-567.
3. Das S, Srikanth M, Kessler JA. Cancer stem cells and glioma. Nat Clin Pract Neurol 2008, 4(8):427-435.
4. Stiles CD, Rowitch DH. Glioma stem cells: a midterm exam. Neuron 2008, 58(6):832-846. 10.1016/j.neuron.2008.05.031, 18579075.
5. Qiu B, Zhang D, Tao J, Tie X, Wu A, Wang Y. Human brain glioma stem cells are more invasive than their differentiated progeny cells in vitro. J Clin Neurosci 2012, 19(1):130-134. 10.1016/j.jocn.2011.06.014, 22153826.
6. Shmelkov SV, St CR, Lyden D, Rafii S. AC133/CD133/Prominin-1. Int J Biochem Cell Biol 2005, 37(4):715-719. 10.1016/j.biocel.2004.08.010, 15694831.
7. Fan X, Salford LG, Widegren B. Glioma stem cells: evidence and limitation. Semin Canc Biol 2007, 17(3):214-218.
8. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, Aigner L, Brawanski A, Bogdahn U, Beier CP. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Canc Res 2007, 67(9):4010-4015.
9. Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, Becker N, Lichter P, Unterberg A, Radlwimmer B, Herold-Mende CC. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Canc Res 2008, 14(1):123-129.
10. Binello E, Germano IM. Targeting glioma stem cells: a novel framework for brain tumors. Canc Sci 2011, 102(11):1958-1966.
11. Wang J, Wakeman TP, Lathia JD, Hjelmeland AB, Wang XF, White RR, Rich JN, Sullenger BA. Notch promotes radioresistance of glioma stem cells. Stem Cells 2010, 28(1):17-28. 2825687, 19921751.
12. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Canc 2005, 5(4):275-284.
13. Alam J, Stewart D. Nrf2, a Cap'n'Collar transcription factor, regulates induction of the heme oxygenase-1 gene. J Biol Chem 1999, 274(37):26071-26078. 10.1074/jbc.274.37.26071, 10473555.
14. Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 2007, 47:89-116. 10.1146/annurev.pharmtox.46.120604.141046, 16968214.
15. Motohashi H, Yamamoto M. Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol Med 2004, 10(11):549-557. 10.1016/j.molmed.2004.09.003, 15519281.
16. Zhao F, Wu T, Lau A, Jiang T, Huang Z, Wang XJ, Chen W, Wong PK, Zhang DD. Nrf2 promotes neuronal cell differentiation. Free Radic Biol Med 2009, 47(6):867-879. 10.1016/j.freeradbiomed.2009.06.029, 2748111, 19573594.
17. Zhou Y, Wang HD, Zhu L, Cong ZX, Li N, Ji XJ, Pan H, Wang JW, Li WC. Knockdown of Nrf2 enhances autophagy induced by temozolomide in U251 human glioma cell line. Oncol Rep 2013, 29(1):394-400.
18. Pan H, Wang H, Zhu L, Wang X, Cong Z, Sun K, Fan Y. The involvement of Nrf2?ARE pathway in regulation of apoptosis in human glioblastoma cell U251. Neurol Res 2013, 35(1):71-78. 10.1179/1743132812Y.0000000094, 23006842.
19. Velpula KK, Rehman AA, Chelluboina B, Dasari VR, Gondi CS, Rao JS, Veeravalli KK. Glioma stem cell invasion through regulation of the interconnected ERK, integrin alpha6 and N-cadherin signaling pathway. Cell Signal 2012, 24(11):2076-2084. 10.1016/j.cellsig.2012.07.002, 22789454.
20. Lathia JD, Hitomi M, Gallagher J, Gadani SP, Adkins J, Vasanji A, Liu L, Eyler CE, Heddleston JM, Wu Q, et al. Distribution of CD133 reveals glioma stem cells self-renew through symmetric and asymmetric cell divisions. Cell Death Dis 2011, 2:e200. 10.1038/cddis.2011.80, 3186899, 21881602.
21. Mao XG, Yan M, Xue XY, Zhang X, Ren HG, Guo G, Wang P, Zhang W, Huo JL. Overexpression of ZNF217 in glioblastoma contributes to the maintenance of glioma stem cells regulated by hypoxia-inducible factors. Lab Invest 2011, 91(7):1068-1078. 10.1038/labinvest.2011.56, 21483406.
22. Oesterle EC, Campbell S, Taylor RR, Forge A, Hume CR. Sox2 and JAGGED1 expression in normal and drug-damaged adult mouse inner ear. J Assoc Res Otolaryngol 2008, 9(1):65-89. 10.1007/s10162-007-0106-7, 2536811, 18157569.
23. Episkopou V. SOX2 functions in adult neural stem cells. Trends Neurosci 2005, 28(5):219-221. 10.1016/j.tins.2005.03.003, 15866195.
24. He J, Shan Z, Li L, Liu F, Liu Z, Song M, Zhu H. Expression of glioma stem cell marker CD133 and O6-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas. Oncol Rep 2011, 26(5):1305-1313.
25. Folkins C, Man S, Xu P, Shaked Y, Hicklin DJ, Kerbel RS. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Canc Res 2007, 67(8):3560-3564.
26. Park DM, Rich JN. Biology of glioma cancer stem cells. Mol Cells 2009, 28(1):7-12. 10.1007/s10059-009-0111-2, 19655094.
27. Yang L, Lin C, Wang L, Guo H, Wang X. Hypoxia and hypoxia-inducible factors in glioblastoma multiforme progression and therapeutic implications. Exp Cell Res 2012, 318(19):2417-2426. 10.1016/j.yexcr.2012.07.017, 22906859.
28. Heddleston JM, Wu Q, Rivera M, Minhas S, Lathia JD, Sloan AE, Iliopoulos O, Hjelmeland AB, Rich JN. Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential. Cell Death Differ 2012, 19(3):428-439. 10.1038/cdd.2011.109, 3229666,3229666, 21836617.
29. Soeda A, Park M, Lee D, Mintz A, Androutsellis-Theotokis A, McKay RD, Engh J, Iwama T, Kunisada T, Kassam AB, et al. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene 2009, 28(45):3949-3959. 10.1038/onc.2009.252, 19718046.
30. Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, Shi Q, Cao Y, Lathia J, McLendon RE, et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Canc Cell 2009, 15(6):501-513.
31. Reddy NM, Kleeberger SR, Cho HY, Yamamoto M, Kensler TW, Biswal S, Reddy SP. Deficiency in Nrf2-GSH signaling impairs type II cell growth and enhances sensitivity to oxidants. Am J Respir Cell Mol Biol 2007, 37(1):3-8. 10.1165/rcmb.2007-0004RC, 1899352, 17413030.
32. Santos DM, Santos MM, Moreira R, Sola S, Rodrigues CM. Synthetic condensed 1,4-naphthoquinone derivative shifts neural stem cell differentiation by regulating redox state. Mol Neurobiol 2013, 47(1):313-324. 10.1007/s12035-012-8353-y, 23054678.
33. Tsai JJ, Dudakov JA, Takahashi K, Shieh JH, Velardi E, Holland AM, Singer NV, West ML, Smith OM, Young LF, et al. Nrf2 regulates haematopoietic stem cell function. Nat Cell Biol 2013, 15(3):309-316. 10.1038/ncb2699, 3699879, 23434824.
34. Merchant AA, Singh A, Matsui W, Biswal S. The redox-sensitive transcription factor Nrf2 regulates murine hematopoietic stem cell survival independently of ROS levels. Blood 2011, 118(25):6572-6579. 10.1182/blood-2011-05-355362, 3242719, 22039262.
35. Kato K, Takahashi K, Monzen S, Yamamoto H, Maruyama A, Itoh K, Kashiwakura I. Relationship between radiosensitivity and Nrf2 target gene expression in human hematopoietic stem cells. Radiat Res 2010, 174(2):177-184. 10.1667/RR2146.1, 20681784.
36. Wang Y, Guan Y, Wang F, Huang A, Wang S, Zhang YA. Bmi-1 regulates self-renewal, proliferation and senescence of human fetal neural stem cells in vitro. Neurosci Lett 2010, 476(2):74-78. 10.1016/j.neulet.2010.04.006, 20385206.
37. Cox JL, Mallanna SK, Ormsbee BD, Desler M, Wiebe MS, Rizzino A. Banf1 is required to maintain the self-renewal of both mouse and human embryonic stem cells. J Cell Sci 2011, 124(Pt 15):2654-2665. 3138706, 21750191.
38. Kemper K, Sprick MR, de Bree M, Scopelliti A, Vermeulen L, Hoek M, Zeilstra J, Pals ST, Mehmet H, Stassi G, et al. The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Canc Res 2010, 70(2):719-729.
39. Park D, Xiang AP, Mao FF, Zhang L, Di CG, Liu XM, Shao Y, Ma BF, Lee JH, Ha KS, et al. Nestin is required for the proper self-renewal of neural stem cells. Stem Cells 2010, 28(12):2162-2171. 10.1002/stem.541, 20963821.
40. Tropepe V, Sibilia M, Ciruna BG, Rossant J, Wagner EF, van der Kooy D. Distinct neural stem cells proliferate in response to EGF and FGF in the developing mouse telencephalon. Dev Biol 1999, 208(1):166-188. 10.1006/dbio.1998.9192, 10075850.
41. Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, Shi Q, McLendon RE, Bigner DD, Rich JN. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Canc Res 2006, 66(16):7843-7848.
42. Bao S, Wu Q, Li Z, Sathornsumetee S, Wang H, McLendon RE, Hjelmeland AB, Rich JN. Targeting cancer stem cells through L1CAM suppresses glioma growth. Canc Res 2008, 68(15):6043-6048.
43. Yu SC, Xiao HL, Jiang XF, Wang QL, Li Y, Yang XJ, Ping YF, Duan JJ, Jiang JY, Ye XZ, et al. Connexin 43 reverses malignant phenotypes of glioma stem cells by modulating E-cadherin. Stem Cells 2012, 30(2):108-120. 10.1002/stem.1685, 22131169.
44. Aguado T, Carracedo A, Julien B, Velasco G, Milman G, Mechoulam R, Alvarez L, Guzman M, Galve-Roperh I. Cannabinoids induce glioma stem-like cell differentiation and inhibit gliomagenesis. J Biol Chem 2007, 282(9):6854-6862.
45. Wang J, Wang H, Li Z, Wu Q, Lathia JD, McLendon RE, Hjelmeland AB, Rich JN. c-Myc is required for maintenance of glioma cancer stem cells. PLoS One 2008, 3(11):e3769. 10.1371/journal.pone.0003769, 2582454, 19020659.
46. Clement V, Sanchez P, de Tribolet N, Radovanovic I, Ruiz IAA. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol 2007, 17(2):165-172. 10.1016/j.cub.2006.11.033, 1855204, 17196391.
47. Zhang XP, Zheng G, Zou L, Liu HL, Hou LH, Zhou P, Yin DD, Zheng QJ, Liang L, Zhang SZ, et al. Notch activation promotes cell proliferation and the formation of neural stem cell-like colonies in human glioma cells. Mol Cell Biochem 2008, 307(1-2):101-108.
48. Cullinan SB, Zhang D, Hannink M, Arvisais E, Kaufman RJ, Diehl JA. Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival. Mol Cell Biol 2003, 23(20):7198-7209. 10.1128/MCB.23.20.7198-7209.2003, 230321, 14517290.